Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleozen for Prevention and Treatment of PTSD
NCT03724448Phase 1Completed
- Sponsor
- Hôpital Universitaire Sahloul
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing ALEOZEN group with placebo group (2 arms). Primary endpoint: Clinician-Administered PTSD Scale at 6 months. Started Jun 2018; status: completed.
02
Drugs
Aleozen
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03724448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724448.